MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	10 63.808
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-23M 169M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First Quarter Net Rose On Strong Demand

15. apr 2026, 17:13 UTC

Suurimad hinnamuutused turgudel

Tesla Shares Rise on Completion of AI5 Chip Design Process

15. apr 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15. apr 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15. apr 2026, 22:41 UTC

Tulu

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15. apr 2026, 22:38 UTC

Tulu

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15. apr 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. apr 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15. apr 2026, 22:14 UTC

Tulu

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15. apr 2026, 22:12 UTC

Tulu

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology Swings to Loss in 1Q>300433.SZ

15. apr 2026, 22:07 UTC

Tulu

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15. apr 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15. apr 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15. apr 2026, 20:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. apr 2026, 20:30 UTC

Tulu

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. apr 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15. apr 2026, 19:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15. apr 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15. apr 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15. apr 2026, 18:58 UTC

Market Talk

Uudisväärsed sündmused

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15. apr 2026, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15. apr 2026, 17:45 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15. apr 2026, 16:58 UTC

Tulu

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15. apr 2026, 16:52 UTC

Tulu

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15. apr 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15. apr 2026, 16:37 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.